Page last updated: 2024-12-07
adn 138
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
ADN 138: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 127323 |
CHEMBL ID | 143895 |
SCHEMBL ID | 10367313 |
MeSH ID | M0154184 |
Synonyms (13)
Synonym |
---|
adn 138 |
adn-138 |
CHEMBL143895 |
99434-90-9 |
8'-chloro-2',3'-dihydrospiro(pyrrolidine-3,6'(5'h)-pyrrolo(1,2,3-de)(1,4)benzoxazine)-2,5,5'-trione |
spiro(pyrrolidine-3,6'(5'h)-pyrrolo(1,2,3-de)(1,4)benzoxazine)-2,5,5'-trione, 8'-chloro-2',3'-dihydro- |
8'-chloro-2',3'-dihydrospiro[pyrrolidine-3,6'(5'h)-pyrrolo[1,2,3-de][1,4]benzoxazine]-2,5,5'-trione |
WSLOHMLGIVSUPR-UHFFFAOYSA-N |
SCHEMBL10367313 |
8-chloro-5'-hydroxy-2,3-dihydro-5h-spiro[1,4-oxazino[2,3,4-hi]indole-6,3'-pyrrole]-2',5(4'h)-dione |
DTXSID00912710 |
6-chlorospiro[9-oxa-1-azatricyclo[6.3.1.04,12]dodeca-4(12),5,7-triene-3,3'-pyrrolidine]-2,2',5'-trione |
AKOS040750148 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (5)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID181872 | In vivo galactitol inhibitory activity measured by its ability to inhibit galactitol accumulation in sciatic nerve at 10 mg/kg/day | 1992 | Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24 | Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents. |
AID34355 | In vitro aldose reductase inhibitory activity measured by NADPH-dependent inhibition of glyceraldehyde reduction in a partially purified bovine lens preparation at 10E-7 M | 1992 | Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24 | Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents. |
AID184345 | In vivo galactitol inhibitory activity measured by its ability to inhibit galactitol accumulation in lens at 10 mg/Kg/day | 1992 | Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24 | Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents. |
AID184326 | In vivo galactitol inhibitory activity measured by its ability to inhibit galactitol accumulation in diaphragm at 10 mg/kg/day | 1992 | Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24 | Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents. |
AID34354 | In vitro aldose reductase inhibitory activity measured by NADPH-dependent inhibition of glyceraldehyde reduction in a partially purified bovine lens preparation at 10E-6 M | 1992 | Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24 | Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (60.00) | 18.7374 |
1990's | 2 (40.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 52.35
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (52.35) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |